Cladis Investment Advisory’s Eli Lilly LLY Stock Holding History

Cladis Investment Advisory’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.81M	Sell	4,142 -510	-11%	-$517K	2.1%	7
2025 Q4	$5M	Sell	4,652 -7	-0.2%	-$6.69K	2.74%	4
2025 Q3	$3.56M	Buy	4,659 +15	+0.3%	+$11.2K	2.03%	7
2025 Q2	$3.62M	Hold	4,644	–	–	2.27%	6
2025 Q1	$3.84M	Hold	4,644	–	–	2.78%	5
2024 Q4	$3.59M	Sell	4,644 -300	-6%	-$248K	2.54%	5
2024 Q3	$4.38M	Sell	4,944 -900	-15%	-$809K	3.04%	4
2024 Q2	$5.29M	Hold	5,844	–	–	3.84%	3
2024 Q1	$4.55M	Sell	5,844 -1,017	-15%	-$724K	3.34%	3
2023 Q4	$4M	Sell	6,861 -100	-1%	-$58.4K	3.14%	3
2023 Q3	$3.74M	Buy	6,961 +44	+0.6%	+$22.7K	3.28%	2
2023 Q2	$3.24M	Hold	6,917	–	–	2.82%	3
2023 Q1	$2.38M	Buy	6,917 +30	+0.4%	+$10.1K	2.13%	5
2022 Q4	$2.52M	Sell	6,887 -230	-3%	-$81.5K	2.51%	3
2022 Q3	$2.3M	Buy	7,117 +47	+0.7%	+$14.9K	2.49%	3
2022 Q2	$2.29M	Hold	7,070	–	–	2.29%	4
2022 Q1	$2.02M	Sell	7,070 -500	-7%	-$129K	1.64%	14
2021 Q4	$2.09M	Buy	+7,570	New	+$1.92M	1.68%	12

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Cladis Investment Advisory's LLY Position: Q1 2026 in Review

Cladis Investment Advisory reduced its Eli Lilly (LLY) stake by 11% in Q1 2026, selling an estimated $517K and leaving 4,142 shares worth $3.81M. The position accounts for 2.1% of the portfolio, ranked #7.

Cladis Investment Advisory first reported a position in LLY in Q4 2021 and has held it in 18 quarters since. The position peaked at $5.29M in Q2 2024. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

Cladis Investment Advisory held 4,142 shares of Eli Lilly worth $3.81M as of Q1 2026.
Cladis Investment Advisory sold 510 Eli Lilly shares in Q1 2026, an estimated $517K.
Eli Lilly made up 2.1% of Cladis Investment Advisory's portfolio in Q1 2026, its #7 holding.
Cladis Investment Advisory first reported a position in Eli Lilly in Q4 2021 and has held it in 18 quarters since.
Cladis Investment Advisory's Eli Lilly position peaked at $5.29M in Q2 2024.
4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Cladis Investment Advisory's 13F filing for Q1 2026, filed 15 May 2026.